Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

Por Heinzerling, L, Kühnapfel, S, Meckbach, D, Baiter, M, Kaempgen, E, Keikavoussi, P, Schuler, G, Agaimy, A, Bauer, J, Hartmann, A, Kiesewetter, F, Schneider-Stock, R
Publicado em 2013

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Por Rutkowski, S, De Vleeschouwer, S, Kaempgen, E, Wolff, J E A, Kühl, J, Demaerel, P, Warmuth-Metz, M, Flamen, P, Van Calenbergh, F, Plets, C, Sörensen, N, Opitz, A, Van Gool, S W
Publicado em 2004

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Por Leyvraz, S., Piperno-Neumann, S., Suciu, S., Baurain, J. F., Zdzienicki, M., Testori, A., Marshall, E., Scheulen, M., Jouary, T., Negrier, S., Vermorken, J. B., Kaempgen, E., Durando, X., Schadendorf, D., Gurunath, R. Karra, Keilholz, U.
Publicado no Ann Oncol (2014)

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells

Por Janetzki, Sylvia, Price, L., Britten, C. M., van der Burg, S. H., Caterini, J., Currier, J. R., Ferrari, G., Gouttefangeas, C., Hayes, P., Kaempgen, E., Lennerz, V., Nihlmark, K., Souza, V., Hoos, A.
Publicado em 2009